ClinPhar Flashcards
WHICH OF THE FOLLOWING IS NOT A SKILL REQUIRED FOR A CLINICAL PHARMACIST?
A. THERAPEUTIC PLANNING
B. DIAGNOSTIC
C. DRUG MONITORING
D. COMMUNICATION
E. NO CORRECT ANSWER
B. DIAGNOSTIC
WHICH OF THE FOLLOWING IS NOT A GOAL OF PHARMACEUTICAL CARE?
A. ELIMINATION OF SYMPTOMS
B. CURE OF DISEASE
C. REDUCTION OF HEALTH CARE COSTS
D. PREVENTION OF DISEASE
E. NO CORRECT ANSWER
C. REDUCTION OF HEALTH CARE COSTS
STAGE I HYPERTENSION
A. 120-139 MMHG AND 80-89 MMHG
B. 120-139 MMHG OR 80-89 MMHG
C. 140-159 MMHG OR 90-99 MMLG
D. 140-159 MMHG AND 90-99 MMHG
C. 140-159 MMHG OR 90-99 MMLG
AN ERROR OCCURRED THAT RESULTED IN EITHER AN INITIAL OR PROLONGED HOSPITALIZATION, LEADING TO TEMPPRARY HARM TO THE PATIENT.
A. CAT G
B. CAT H
C. CAT F
D. CAT E
C. CAT F
WHICH OF THE FOLLOWING AREA DOESN’T FOLLOW THE IPPA FORMAT?
A. CHEST
B. ABDOMEN
C. NECK
D. AOTA
B. ABDOMEN
ALL ARE TRUE WHEN TAKING FAMILY HISTORY, EXCEPT;
A. ONLY FIRST DEGREE MEMBERS
B. INCLUDE THOSE WHO PASSED AWAY
C. SIBLINGS AND PARENTS HISTORY
D. NO EXCEPTION
D. NO EXCEPTION
THALIDOMIDE WAS FAMOUS IN THE LATE 1950S TO EARLY 60S AS DRUG FOR WHAT?
A. MORNING SICKNESS
B. FLU
C. NERVE DAMAGE
D. PNEUMONIA
A. MORNING SICKNESS
HIRSUTISM FROM MINOXIDIL IS WHAT TYPE OF ADR?
A. TYPE A
B. ТУРЕ B
C. TYPE C
D. TYPE D
A. TYPE A
WHICH OF THE FOLLOWING IS CORRECT FOR STAGE 4 CKD CRCL?
A. eGFR 10-19
B. eGFR 15-29
C. eGFR 30-39
D. eGFR LESS THAN 20
B. eGFR 15-29
WHICH OF THE FOLLOWING DRUGS DOESN’T REQUIRE TDM?
A. DILTIAZEM
B. PHENYTOIN
C. METHOTREXATE
D. THEOPHYLLINE
A. DILTIAZEM
ALSO KNOWN AS LONGITUDINAL STUDY or “PROSPECTIVE STUDY”
A. CROSS SECTIONAL
B. CASE CONTROL
C. COHORT
D. CLINICAL TRIAL
C. COHORT
THE FOLLOWING IS CORRECTLY PAIRED, EXCEPT?
A. LAGUNDI – COUGH
B. SAMBONG – DIURETIC
C. TSAANG GUBAT – ANTIDIARRHEAL
D. BANABA – ANTI-GOUT
D. BANABA – ANTI-GOUT
GOLD STANDARD OF STUDY DESIGNS
A. CROSS SECTIONAL
B. CASE CONTROL
C. COHORT
D. CLINICAL TRIAL
D. CLINICAL TRIAL
COMPONENTS OF EVIDENCE BASED MEDICINE
I. CLINICAL EXPERTISE
II. PATIENT VALUES
III. BEST EVIDENCE
IV. RESEARCH DESIGNS
A. I, II, AND III
B. I, II, AND IV
C. I, II, AND IV
D. I AND III
A. I, II, AND III
URINE WHEN TAKING STATINS?
A. PALE YELLOW
B. DARK BROWN
C. RED
D. TURBID
B. DARK BROWN
WHICH OF THE FOLLOWING IS CORRECT ARRANGE FROM LEAST TO HIGHEST FORM OF EVIDENCE?
A. RCTs, SYSTEMATIC REVIEWS, META-ANALYSIS
B. COHORT, CASE REPORTS, RCTS
C. OPINION, COHORT, CASE STUDIES
D. ALL ARE CORRECT
A. RCTs, SYSTEMATIC REVIEWS, META-ANALYSIS
MEASURES CONSEQUENCES IN TERMS OF QUALITY ADJUSTED LIFE YEAR (QALY) GAINED.
A. COST MINIMIZATION
B. COST EFFECTIVENESS
C. COST UTILIZATION
D. COST BENEFIT
C. COST UTILIZATION
BLEEDING TYPICALLY ORIGINATES FROM THE UPPER (GI) TRACT, INCLUDING THE MOUTH, ESOPHAGUS, STOMACH, AND THE FIRST PART OF THE SMALL INTESTINES WILL RESULT TO:
A. BLACK, TARRY STOOL
B. REDDISH STOOL
C. DARK BROWN STOOL
D. NO CORRECT ANSWER
A. BLACK, TARRY STOOL
WHICH OF THE FOLLOWING INCREASES DURING PARASITIC INFECTIONS?
A. NEUTROPHILS
B. LYMPHOCYTES
C. EOSINOPHILS
D. BASOPHILS
C. EOSINOPHILS
LDH FRACTION THAT ELEVATES DURING RHABDOMYOLYSIS
A. LDH 1
B. LDH 3
C. LDH 4
D. LDH 2
D. LDH 2
WHICH OF THE FOLLOWING DOESN’T LEAD TO DECREASE IN HEMATOCRIT?
A. POLYCETHEMIA VERA
B. HEMOLYSIS
C. OVERHYDRATION
D. BLOOD LOSS
A. POLYCETHEMIA VERA
WARFARIN INHIBITS FORMATION OF CLOTTING FACTORS, EXCEPT;
A. IX
B. X
C. VII
D. III
D. III
TRUE FOR CARDIAC TROPONIN I
I. PROLONGED ELEVATION
II. MORE SPECIFIC FOR THE HEART
III. INCREASES DURING RHABDOMYOLYSIS
IV. INCREASES DURING MI
A. I, II AND III
B. I, III AND IV
C. I, II AND IV
D. I AND II ONLY
C. I, II AND IV
WHICH OF THE FOLLOWING IS BIOLOGICAL PRODUCT COMMONLY GIVEN TO TREAT RHEUMATOID ARTHRITIS?
A. INFLIXIMAB
B. PENICILLAMINE
C. METHOTREXATE
D. SULFASALAZINE
A. INFLIXIMAB
RESPONSIBLE FOR THE COLORATION OF FECES
A. STERCOBILIN
B. UROBILIN
C. UROBILINOGEN
D. NO CORRECT ANSWER
A. STERCOBILIN
TRUE FOR CONJUGATED BILIRUBIN, EXCEPT;
A. USUALLY CAUSED BY OBSTRUCTIVE DISEASE
B. WATER SOLUBLE
C. REQUIRE CARRIER FOR TRANSPORT
D. METABOLIZED BY LIVER
C. REQUIRE CARRIER FOR TRANSPORT
WHICH OF THE FOLLOWING IS INCORRECT FOR FBS?
A. REQUIRES FASTING FOR AT LEAST 5 HOURS
B. YOU MAY DRINK WATER DURING THE FASTING TIME
C. MORE THAN 126 MG/DL IS CONSIDERED POSITIVE FOR DM
D. NORMAL READING SHOULD BE BELOW 100 MG/DL
A. REQUIRES FASTING FOR AT LEAST 5 HOURS
THIS IS THE MOST PREDOMINANT EXTRACELLULAR ANION?
A. PHOSPHATE
B. CHLORIDE
C. SULFATE
D. BICARBONATE
B. CHLORIDE
CAUSES OF HYPERKALEMIA EXCEPT;
A. K-SPARING DIURETICS
B. NSAIDS
C. KIDNEY FAILURE
D. CALCIUM CHANNEL BLOCKERS
D. CALCIUM CHANNEL BLOCKERS
WHICH OF THE FOLLOWING CAN BE SEEN IN INCREASE PTH, EXCEPT?
A. ⬆ CA
B. ⬆ РО4
C. ⬇ РО4
D. NO EXCEPTION
B. ⬆ РО4
WHICH OF THE FOLLOWING STATEMENTS IS INCORRECT FOR HPN?
A. INCREASE IN CARDIAC OUTPUT, INCREASE BLOOD PRESSURE
B. INCREASE IN VASCULAR RESISTANCE, INCREASE BLOOD PRESSURE
C. DECREASE HEART RATE, REDUCE CARDIAC OUTPUT
D. DECREASE STROKE VOLUME, INCREASE BLOOD PRESSURE
D. DECREASE STROKE VOLUME, INCREASE BLOOD PRESSURE
WHICH OF THE FOLLOWING HAS NO CONTRAINDICATION WITH USE OF BETA BLOCKERS?
A. ELECTROLYTE IMBALANCE
B. ASTHMA
C. DIABETES
D. ARTHRITIS
D. ARTHRITIS
DRUG OF CHOICE FOR GESTATIONAL HYPERTENSION?
A. NIFEDIPINE
B. METHYLDOPA
C. CAPTOPRIL
D. THIAZIDES
B. METHYLDOPA
WHAT IS THE 2ND LINE OF TREATMENT FOR TYPE II DM?
A. METFORMIN
B. LIFESTYLE MODIFICATION
C. ADDITION OF SULFONYLUREA
D. NO CORRECT ANSWER
A. METFORMIN
WHICH IS NOT A COMPLICATION OF DIABETES?
A. RETINOPATHY
B. NEPHROPATHY
C. NEUROPATHY
D. NO CORRECT ANSWER
D. NO CORRECT ANSWER
CLASSIFICATION OF ASTHMA WHEREIN THERE IS A DAILY EXACERBATIONS
A. MODERATE PERSISTENT
B. MILD PERSISTENT
C. SEVERE PERSISTENT
D. INTERMITTENT
MODERATE PERSISTENT
WHICH IS NOT A TRIAD OF COPD?
A. EMPHYSEMA
B. BRONCHITIS
C. ASTHMA
D. TUBERCULOSIS
D. TUBERCULOSIS
TRUE FOR EMPHYSEMA, EXCEPT
A. PINK PUFFERS
B. TISSUE HYPOXIA
C. INCREASE VENTILATION
D. INCREASE CARDIAC OUTPUT
D. INCREASE CARDIAC OUTPUT
DRUGS TO MANAGE PARKINSON EXCEPT?
A. ANTICHOLINERGICS
B. SELEGILINE
C. AMATIDINE
D. BETA BLOCKER
D. BETA BLOCKER
CAUSATIVE AGENT/S OF MENINGITIS EXCEPT?
A. NEISSERIA MININGITIDIS
B. STREPTOCOCCUS PNEUMONIAE
C. LISTERIA MONOCYTOGENES
D. NO EXCEPTION
D. NO EXCEPTION
WHICH OF THE FOLLOWING IS NOT A SKILL REQUIRED FOR A CLINICAL PHARMACIST?
A. DRUG MONITORING
B. NON-DRUG THERAPY
C. COMMUNICATION
D. THERAPEUTIC PLANNING
B. NON-DRUG THERAPY
ERROR OCCURRED THAT RESULTED IN NEAR DEATH EVENT
A. CAT F
B. CAT I
C. CAT G
D. CAT H
D. CAT H
WHICH OF THE FOLLOWING AREA DOESN’T FOLLOW THE IPPA FORMAT?
A. CHEST
B. ABDOMEN
C. NECK
D. AOTA
B. ABDOMEN
A STUDY THAT INCOLVES SURVEYING A SPECIFIC POPULATION FOR THE PREVALENCE OF LUNG CANCER AT A SINGLE POINT IN TIME USES WHAT STUDY DESIGN?
A. COHORT
B. CASE CONTROL
C. RANDOMIZED CONTROL TRIAL
D. CROSS-SECTIONAL
D. CROSS-SECTIONAL
THE PRINCIPLE BEHIND COMBINATION OF AMOXICILLIN AND CLAVULANIC ACID?
A. SYNERGISM
B. ANTAGONISM
C. ADDITION
D. POTENTIATION
D. POTENTIATION
WHICH OF THE FOLLOWING MAY CAUSE DRUG-INDUCED KERNICTERUS IN NEONATES?
A. SULFISOXAZOLE
B. ISONIAZID
C. DOXYCYCLINE
D. CHLORAMPHENICOL
A. SULFISOXAZOLE
THE VITAMIN THAT IS USED FOR HYPERLIPIDEMIA?
A. NIACIN
B. PANTOTHENIC ACID
C. FOLIC ACID
D. BIOTIN
A. NIACIN
WARFARIN, WHEN TAKEN TOGETHER WITH LEAFY VEGETABLES, RESULTS TO WHICH OF THE FOLLOWING?
I. INCREASE PT-INR
II. DECREASE PT-INR
III. RISK OF BLEEDING
IV. RISK OF THROMBOSIS
A. I AND III
B. II AND IV
C. I AND IV
D. I AND III
B. II AND IV
THE PHARMACIST WAS REVIEWING A NEW ORDER OF ALDACTONE FOR A PATIENT WHO IS RECEIVING AN ACE INHIBITOR. WHICH OF THE FOLLOWING SIGNIFICANT INTERACTION SHOULD BE NOTED BY THE PHARMACIST?
A. BOTH DRUGS MAY INTERACT TO CAUSE A
DECREASE IN SUGAR LEVELS
B. BOTH DRUGS MAY INTERACT TO CAUSE AN
ELEVATION IN URIC ACID
C. BOTH DRUGS MAY INTERACT TO CAUSE AN
ELEVATION IN BLOOD POTASSIUM LEVELS.
D. ALDACTONE MAY ANTAGONIZE ACE INHIBITOR
C. BOTH DRUGS MAY INTERACT TO CAUSE AN
ELEVATION IN BLOOD POTASSIUM LEVELS.
A DIABETIC PATIENT WITH HTN IS TAKING ENALAPRIL. HOWEVER, HE COMPLAINED OF SEVERE DRY COUGH WITH THE USE OF THE DRUG. WHICH WOULD BE THE BEST ALTERNATIVE DRUG FOR THE PATIENT?
A. LISINOPRIL
B. NIFEDIPINE
C. THIAZIDE
D. LOSARTAN
D. LOSARTAN
CHARACTERIZED BY LOW PROTEIN INTAKE WITH ADEQUATE CALORIC INTAKE
A. KWASHIORKOR
B. MARASMUS
C. SECONDARY MALNUTRITION
D. RICKETS
A. KWASHIORKOR
WHICH OF THE FOLLOWING DEFICIENCIES IS/ARE MOST COMMON CAUSE/S OF MEGALOBLASTIC ANEMIA?
I. IRON DEFICIENCY
II. VITAMIN B12 DEFICIENCY
III. FOLIC ACID DEFICIENCY
A. II
B. II AND III
C. I
D. I, II AND III
B. II AND III
THE FOLLOWING CAN CAUSE HEMOLYTIC ANEMIA, EXCEPT
A. METHYLDOPA
B. METHYLENE BLUE
C. NAPHTHALENE
D. ACETAMINOPHEN
D. ACETAMINOPHEN
BETA BLOCKER OVERDOSE MAY LEAD TO BRADYCARDIA. THIS ADVERSE DRUG REACTION CAN BE CLASSIFIED AS
A. TYPE D
B. TYPE B
C. TYPE C
D. TYPE A
D. TYPE A
THE FOLLOWING OCCURS AT THE THERAPEUTIC DOSE OF THE DRUG EXCEPT:
A. IDIOSYNCRATIC REACTION
B. HYPERSENSITIVITY REACTION
C. SIDE EFFECTS
D. TOXICITY
D. TOXICITY
METFORMIN, AN ORAL HYPOGLYCEMIC AGENT HAS A PROMINENT SIDE EFFECT WHICH COULD INCREASE LEVELS OF WHAT SUBSTANCE?
A. INSULIN
B. HCl
C. URIC ACID
D. LACTIC ACID
D. LACTIC ACID
A PATIENT TAKING NONSELECTIVE BETA-BLOCKERS SHOULD NOT BE USED OR SHOULD CAUTIOUSLY USED IN PATIENTS WITH:
A. ALL ARE CORRECT
B. ATRIOVENTRICULAR BLOCK
C. DIABETES
D. ASTHMA
A. ALL ARE CORRECT
CAUSES OF HYPERKALEMIA, EXCEPT:
A. VASOCONSTRICTORS
B. POTASSIUM SPARING DIURETICS
C. BETA BLOCKERS
D. NSAIDS
A. VASOCONSTRICTORS
PHASE OF DRUG DEVELOPMENT WHICH ASSESS SAFETY IN HEALTHY HUMAN VOLUNTEERS
A. PHASE 1
B. PHASE 2
C. PRE-CLINICAL
D. PHASE 3
A. PHASE 1
DRUG OF CHOICE FOR GESTATIONAL HYPERTENSION?
A. CAPTOPRIL
B. NIFEDIPINE
C. THIAZIDES
D. METHYLDOPA
D. METHYLDOPA
WHICH OF THE FOLLOWING IS BIOLOGICAL PRODUCT COMMONLY GIVEN TO TREAT RHEUMATOID ARTHRITIS?
A. METHOTREXATE
B. PENICILLAMINE
C. SULFASALAZINE
D. INFLIXIMAB
D. INFLIXIMAB
ALSO KNOWN AS RETROSPECTIVE STUDY
A. CASE CONTROL
B. CLINICAL TRIAL
C. CROSS SECTIONAL
D. COHORT
A. CASE CONTROL
MAJORITY OF UROBILINOGEN GOES TO
A. SWEAT
B. URINE
C. ENTEROHEPATIC CIRCULATION
D. FECES
D. FECES
TRUE FOR CONJUGATED BILIRUBIN, EXCEPT:
A. REQUIRE CARRIER FOR TRANSPORT
B. METABOLIZED BY LIVER
C. WATER SOLUBLE
D. USUALLY CAUSED BY OBSTRUCTIVE DISEASE
A. REQUIRE CARRIER FOR TRANSPORT
TRUE FOR PARKINSON’S DISEASE, EXCEPT:
A. NO EXCEPTION
B. ANTICHOLINERGICS MAY IMPROVE
SYMPTOMS
C. PRESENCE OF RESTING TREMORS
D. SLOW MOVEMENT
A. NO EXCEPTION
